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Abstract
Background: Macrocytosis occurs in chronic hemodialysis (CHD) patients; however, its significance is unknown.
The purpose of this study was to establish the prevalence and distribution of macrocytosis, to identify its clinical
associations and to determine if macrocytosis is associated with mortality in stable, chronic hemodialysis patients.
Methods: We conducted a single-centre prospective cohort study of 150 stable, adult CHD patients followed for
nine months. Macrocytosis was defined as a mean corpuscular volume (MCV) > 97 fl. We analyzed MCV as a
continuous variable, in tertiles and using a cutoff point of 102 fl.
Results: The mean MCV was 99.1 ± 6.4 fl, (range 66-120 fl). MCV was normally distributed. 92 (61%) of patients had
an MCV > 97 fl and 45 (30%) > 102 fl. Patients were not B12 or folate deficient in those with available data and three
patients with an MCV > 102 fl had hypothyroidism. In a logistic regression analysis, an MCV > 102 fl was associated
with a higher Charlson-Age Comorbidity Index (CACI) and higher ratios of darbepoetin alfa to hemoglobin (Hb),
[(weekly darbepoetin alfa dose in micrograms per kg body weight / Hb in g/L)*1000]. There were 23 deaths at nine
months in this study. Unadjusted MCV > 102 fl was associated with mortality (HR 3.24, 95% CI 1.42-7.39, P = 0.005).
Adjusting for the CACI, an MCV > 102 fl was still associated with mortality (HR 2.47, 95% CI 1.07-5.71, P = 0.035).
Conclusions: Macrocytosis may be associated with mortality in stable, chronic hemodialysis patients. Future studies
will need to be conducted to confirm this finding.
Background
Anemia is a common consequence of end-stage renal
disease (ESRD). Several causes have been identified
including iron deficiency [1], reduced production of ery-
thropoietin [2], shortened red cell survival [3] and folate
deficiency [4]. Among these, endogenous erythropoietin
deficiency is the predominant cause [2].
Erythropoiesis stimulatinga g e n t s( E S A s )h a v eb e e n
effective in treating the anemia of ESRD [5,6]. However,
despite their use, anemia may still occur and is associated
with significant morbidity and mortality in dialysis patients
[7,8]. Furthermore, higher ESA doses have also been asso-
ciated with increased mortality in hemodialysis patients
[9-11]. Whether the increase in mortality observed with
ESAs is due to achieved hemoglobin, ESA resistance due
to inflammation, a direct effect of erythropoietin,
concurrent administration of intravenous iron or some
other mechanism, is unclear [12].
Morphologically, the anemia of ESRD is typically nor-
mocytic and normochromic [13], but up to 30% [14-16]
may have macrocytosis. Proposed causes of macrocytosis
in dialysis patients include intravenous iron [15,17],
megaloblastic anemia due to B12 and folate deficiency [4]
or dialysis-induced changes in red cell volume [18,19].
Reticulocytosis is associated with macrocytosis in the
general population [20] and initial studies of ESAs sug-
gested stable and predictable increases in reticulocyte
levels with maintenance erythropoietin therapy [21].
However, reticulocytes can also be smaller than mature
red cells [22], and no studies have specifically addressed
the relationship between ESAs and macrocytosis.
While several studies have suggested causes, no stu-
dies have examined for clinical associations with macro-
cytosis in dialysis patients. Furthermore, an association
between red cell size and mortality has not been identi-
fied in previous study [23].
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many patients have an unexplained macrocytosis. The
purpose of this study was to establish the prevalence
and distribution of macrocytosis, to identify its clinical
associations and to determine if macrocytosis is asso-
ciated with mortality in stable, chronic hemodialysis
patients.
Methods
We conducted a single-centre prospective cohort study of
150 adult patients on chronic hemodialysis (defined as
greater than three months). The cohort was derived from
all 195 patients undergoing hemodialysis in our local cen-
tre on October 1
st, 2009. Exclusions are noted in figure 1.
Three measurements of baseline laboratory data including
red blood cell mean corpuscular volume (MCV) were col-
lected monthly from October through December 2009.
Values were subsequently averaged to avoid potential
laboratory error associated with single measurements. Any
individuals that died, were transfused or received a kidney
transplant before completing three sets of blood tests were
censored prior to study analysis (figure 1). Follow up
began from the date of last blood work and patients were
prospectively followed for nine months. This study was
approved by the Queen Elizabeth II Health Sciences Cen-
tre research ethics board, our institutional research ethics
committee.
We collected baseline clinical data including age, gen-
der, race, time on dialysis, hemodialysis access, urea
reduction rate, cause of ESRD and comorbid medical
conditions. Causes of ESRD and comorbid conditions
were extracted from existing patient charts and defini-
tions were at the treating physician’s discretion. For med-
ical comorbidities, we calculated a Charlson-Age
Comorbidity Index (CACI) at baseline in all patients [24].
This index allocates different point scores to 19
individual medical conditions depending on the risk of
mortality with each condition. In addition, one point is
given for each decade > 40 years of age. Included in this
score are common medical comorbidities such as dia-
betes, congestive heart failure, cancer, dementia and per-
ipheral vascular disease. The CACI has been identified as
a mortality predictor in dialysis patients. The lowest mor-
tality is observed at scores ≤ 3 and the highest mortality
at scores ≥ 8 [25]. All hemodialysis patients in our unit
receive darbepoetin alfa, and either iron sucrose or iron
dextran to maintain a target hemoglobin of 110 g/L
(range 100-120 g/L). Doses of both monthly intravenous
iron and darbepoetin alfa averaged over the first three
months were recorded. Medication use including immu-
nosuppressive agents, antiepileptic drugs, insulin, oral
folate and multivitamins was also recorded. MCV was
measured in femtolitres (fl). MCV was calculated using a
Coulter LH 750 hematology analyzer, rounded to the
nearest tenth. This analyzer has a within run coefficient
of variation of ≤ 0.8 fl [26]. Our laboratory definition of
macrocytosis is an MCV > 97 fl (normal range 80-97 fl).
Additional baseline laboratory data available included the
complete blood count (CBC), electrolytes, calcium, phos-
phate, parathyroid hormone, ferritin, percent saturation
of transferrin (tsat), albumin, alkaline phosphatase, hepa-
tocellular liver enzymes and serum glucose. We also col-
lected reticulocyte counts, serum B12, red blood cell
folate and serum thyroid stimulating hormone (TSH)
levels available within one year of study onset (October
1
st, 2009). Finally, we calculated a darbepoetin alfa to
hemoglobin (Hb) ratio for each patient, [(weekly darbe-
poetin alfa dose in micrograms per kg body weight / Hb
in g/L)*1000].
The primary outcomes of this study were all cause mor-
tality and time to death in patients with and without
macrocytosis at baseline. Causes of death were categorized
at the treating physician’s discretion according to the
Canadian Organ Replacement Registry (CORR) diagnostic
codes. CORR uses the ICD-10-CA [27], which is a modi-
fied version of the International Statistical Classification of
Diseases and Related Health Problems, 10th Revision
(ICD-10). In addition to mortality, we also examined for
associations of macrocytosis with the clinical and labora-
tory parameters listed above. Patients were censored at the
time of kidney transplantation.
All statistical analyses were performed using SPSS for
Windows software (SPSS version 15.0, Chicago, IL). We
initially examined MCV both as a continuous variable and
using a cutoff point of > 97 fl. Recognizing the potential
for a nonlinear relationship between macrocytosis and
mortality, we also examined MCV in tertiles using a
Kaplan Meier survival analysis. We subsequently used an
ROC curve to determine the most statistically significant
MCV cutoff point predictive of death. Differences in
195adultpatientsreceiving
HDonOct.1st,2009
Exclusions:45
1.ChronicHDadmittedtohospital:22
2.AcuteHD:10
3.TemporaryHDforPDcomplication:6
4.Bloodtransfusionwithintwomonths:6
5.Recoveringkidneyfunction:1
150patientsincludedin
prospectivecohortonOct.
1st,2009 Censored:0
1.Deathspriortothreebloodsamples:0
2.Transplantspriortothreebloodsamples:0
3.Transfusionspriortothreebloodsamples:0
150patientsanalyzedfor
primaryandsecondary
outcomes
Figure 1 Prospective cohort selection.
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Page 2 of 7baseline characteristics using this MCV cutoff point were
calculated for continuous and categorical variables.
Univariate clinical and laboratory associations were also
determined using a binary logistic regression analysis.
Spearman correlation coefficients were calculated to deter-
mine collinearity between association variables. For highly
correlated variables, only those with the highest statistical
significance were incorporated into a backward condi-
tional multivariate model. A Cox survival analysis was
used to evaluate time to death. Variables associated with
macrocytosis and mortality were chosen for incorporation
into the multivariate Cox survival analysis.
Results
Patient Characteristics
All 150 eligible patients completed three sets of blood
tests prior to study analysis (figure 1). The mean MCV
(average of three values) for all patients was 99.1 ± 6.4
fl, (range 66-120 fl). MCVs for each of the three mea-
surements were 99.0 ± 6.4 fl, 99.1 ± 6.3 fl and 99.2 ±
6 . 4f lw i t ha ni n t r ap a t i e n tv a r i a t i o no f1±0 . 7f l .M C V
was normally distributed (figure 2). Specifically, 92
(61%) of patients had an MCV > 97 fl, 59 (39%) > 100
fl, 45 (30%) > 102 fl and 24 (16%) > 105 fl. TSH, serum
B12 and RBC folate levels were available at baseline in
22 (49%), 21 (47%) and 28 (62%) patients with an MCV
> 102 fl. In those patients with available data, serum
B 1 2a n dR B Cf o l a t el e v e l sw e r en o r m a l .T h r e ep a t i e n t s
had biochemical evidence of hypothyroidism (elevated
T S Ha n dl o wf r e eT 4 ) .R e t i c u l o c y t ec o u n t sw e r eo n l y
available in a few patients.
MCV cutoff point most predictive of death
As a continuous variable in a Cox survival analysis,
unadjusted mean MCV was associated with death (HR
1.08 for each 1 fl increase in MCV, 95% CI 1.01-1.15,
P = 0.024). An MCV > 97 fl was not predictive of higher
mortality, however, a Kaplan Meier survival analysis
demonstrated a significant step up in mortality at the
highest tertile of MCV (figure 3, log rank P = 0.047).
This suggested a nonlinear relationship between MCV
and mortality. Using an ROC curve, the optimal MCV
cutoff point predictive of death was > 102 fl (area under
curve 0.653 ± 0.066, P = 0.019, 95% CI 0.524-0.783).
Baseline characteristics using this MCV cutoff point are
listed in table 1. Univariate associations with an MCV >
102 fl are listed in table 2. After identifying those vari-
ables that were highly correlated, only a history of
malignancy, the darbepoetin alfa to Hb ratio and the
CACI were examined in a binary logistic regression ana-
lysis. A higher CACI and darbepoetin alfa to Hb ratio
remained significantly associated with an MCV > 102 fl
(table 2).
Mortality
There were seven kidney transplants and 23 deaths prior
to last follow up (September 1
st, 2010). The mean MCV
of all transplanted and deceased patients was 94.1 ± 4.4 fl
and 102.1 ± 5.9 fl respectively. Causes of death are noted
in table 3. At last follow up, an MCV > 102 fl was asso-
ciated with increased mortality (log rank P = 0.003).
Kaplan-Meier survival curves above and below an MCV
of 102 fl are noted in figure 4. In a Cox survival analysis,
an MCV > 102 fl was strongly associated with death
(unadjusted HR 3.24 95% CI 1.42-7.39, P = 0.005). Other
variables significantly associated with mortality in this
study included age, stroke, history of malignancy at base-
line, a higher CACI, lower mean albumin, higher mean
Figure 2 Distribution of MCV (fl).M e a nM C Vw a s9 9 . 1±6 . 4f l ,
(range 66-120 fl).
MCV66.7Ͳ96.0fl
MCV96.3Ͳ101.7fl
MCV102.0Ͳ119.7fl
Figure 3 Kaplan Meier survival in tertiles of MCV (fl). Log rank p
= 0.047
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Variable All
(n = 150)
MCV ≤ 102 fl
(n = 105)
MCV > 102 fl
(n = 45)
P
Demographic
Age (years) 65.0 ± 17.0 63.3 ± 17.6 68.9 ± 15.1 0.07
Time on dialysis (months) 34.5 ± 31.8 33.8 ± 34.4 36.4 ± 24.6 0.65
Male n (%) 76 (51) 58 (55) 18 (40) 0.09
Caucasian n (%) 135 (90) 91 (87) 44 (98) 0.04
Fistula as HD access n (%)* 45 (30) 33 (31) 12 (27) 0.56
Cause of ESRD n (%)
Diabetes 51 (34) 40 (38) 11 (24) 0.11
Glomerulonephritis 29 (19) 18 (17) 11 (24) 0.30
Comorbidities n (%)
Diabetes 63 (42) 45 (43) 18 (40) 0.75
Hypertension 114 (76) 79 (75) 35 (78) 0.74
Coronary artery disease 53 (35) 39 (37) 14 (31) 0.54
Peripheral vascular disease 33 (22) 23 (22) 10 (22) 0.97
Stroke 21 (14) 14 (13) 7 (16) 0.72
Cancer 25 (17) 11 (10) 14 (31) < 0.01
Failed renal transplant 25 (17) 20 (19) 5 (11) 0.24
Charlson-Age Comorbidity Index 7 ± 3 6 ± 3 8 ± 3 0.01
Laboratory
Mean MCV (fl) 99.1 ± 6.4 96.0 ± 4.6 106.3 ± 3.1 < 0.01
Albumin (g/L) 33.7 ± 3.5 34.0 ± 3.6 33.0 ± 3.3 0.14
Hemoglobin (Hb) (g/L) 108.6 ± 10.0 109.8 ± 10.0 105.7 ± 9.6 0.02
Hb btw. 100-120 g/L n (%) 103 (69) 73 (70) 30 (67) 0.65
Ferritin ug/L 729 ± 467 707 ± 454 782 ± 498 0.37
Tsat (%) 29.77 ± 11.80 28.05 ± 11.37 33.76 ± 11.93 < 0.01
Darbepoetin alfa to Hb ratio 5.37 ± 3.66 4.80 ± 3.49 6.69 ± 3.73 < 0.01
Medications
Darbepoetin alfa dose mcg/week 43.0 ± 31.5 39.3 ± 31.1 51.6 ± 31.1 0.03
Receiving darbepoetin alfa n (%)
+ 141 (94) 97 (92) 44 (98) 0.27
Receiving intravenous iron n (%)
+ 137 (91) 96 (91) 41 (91) 0.95
Antiepileptic n (%) 5 (3) 1 (1) 4 (9) 0.01
On folate n (%) 148 (99) 103 (98) 45 (100) 0.81
On multivitamin 143 (95) 101 (96) 42 (93) 0.26
*Patients without a fistula were dialyzed using a tunnelled, cuffed catheter, except for one using an AV graft
+Received at least one dose during initial three months of study
Continuous variables are reported as means ± standard deviation
Table 2 Univariate and Multivariate Associations with MCV > 102 fl
Univariate (OR [95% CI]) P Multivariate (OR [95% CI]) P
Malignancy* 3.86 [1.59, 9.38] 0.003 2.12 [0.73, 6.17] 0.168
Darbepoetin alfa to Hb ratio 1.15 [1.04, 1.27] 0.005 1.19 [1.07, 1.32] 0.001
Charlson-Age Comorbidity Index 1.18 [1.04, 1.33] 0.012 1.23 [1.07, 1.40] 0.003
Transferrin saturation 1.04 [1.01, 1.07] 0.013 —
Age 60 and above 3.34 [1.42, 7.86] 0.006 —
Antiepileptic medication 10.15 [1.10, 93.51] 0.041 —
Mean hemoglobin (g/L) 0.96 [0.93, 1.00] 0.025 —
Weekly darbepoetin alfa dose (mcg) 1.01 [1.00, 1.02] 0.033 —
Weekly weight adjusted darbepoetin alfa dose (mcg/kg) 3.21 [1.29, 7.98] 0.012 —
* Hematologic and non-hematologic
Variables included in the multivariate binary regression analysis: Malignancy, Darbepoetin alfa to Hb ratio and the Charlson-Age Comorbidity Index.
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Page 4 of 7ferritin, lower levels of uric acid and lower body weight.
The darbepoetin alfa to Hb ratio was not associated with
mortality in this study. After adjusting for the CACI, an
MCV > 102 fl remained significantly associated with
mortality (HR 2.47, 95% CI 1.07-5.71, p = 0.035).
Discussion
In this study of stable, chronic hemodialysis patients, we
identified a high prevalence of unexplained macrocytosis
associated with a higher CACI and higher ratios of
weekly weight adjusted darbepoetin alfa to Hb. Macro-
cytosis both as a continuous variable and using a cutoff
point of 102 fl was associated with higher all-cause
mortality.
While the etiology of macrocytosis or its association
with mortality in our population is unclear, several possi-
bilities need to be considered. Macrocytosis was associated
with a higher CACI at baseline that in turn, was associated
with increased mortality. Perhaps macrocytosis is a
response to underlying illness, and serves as a “window”
into the bone marrow of an elderly dialysis patient with
multiple comorbidities. The macrocytic response may not
be a spontaneous development, rather, an effect of
exogenous ESA administration to a chronically unwell
patient. This would explain the association between MCV
> 102 fl and higher darbepoetin alfa to Hb ratios, the latter
reflecting ESA resistance perhaps due to underlying medi-
cal illness.
Regarding other possible causes, we did identify a uni-
variate association between tsat and macrocytosis. Intra-
venous iron has been linked to increased mortality in
dialysis patients [12,28,29], and has been suggested as a
cause of macrocytosis [15,17]. However, in this study,
mean iron dose over three months at baseline was not
associated with an MCV > 102 fl. As well, there did
appear to be a univariate association between macrocy-
tosis and a history of malignancy, which in turn, was
associated with mortality in this study. Macrocytosis
occurs in certain malignancies, either independently or
as a consequence of chemotherapy [30]. However, 11/14
macrocytic patients in our study with a history of malig-
nancy did not have active cancer at the time of study,
and no patients were actively receiving chemotherapy.
Furthermore, only one death was directly attributable to
cancer amongst the patients with an MCV > 102 fl.
A final consideration is that macrocytosis may be a
manifestation of altered hematopoiesis. In one study of
non-dialysis elderly patients, 25/49 with unexplained
macrocytosis had dysplastic changes or findings consis-
tent with MDS on bone marrow biopsy [31]. Alterna-
tively, altered hematopoiesis may be due to high doses
of ESAs. Macrocytosis due to suspected abnormal rapid
cellular maturation in states of massive erythropoietic
stimulation has been observed in rat models [22], and
we did observe an association between darbepoetin alfa
dose and MCV > 102 fl. However, altered hematopoiesis
was not confirmed with bone marrow biopsy in this
study. Furthermore, bone marrow dysplasia was not
identified in an earlier study of dialysis patients treated
with recombinant erythropoietin for 24 months who
subsequently underwent bone marrow biopsy [32]. In
addition, macrocytosis in dialysis patients has been iden-
tified prior to the introduction of ESAs [17].
As a predictor of increased mortality, macrocytosis
does have advantages over other laboratory markers
commonly used in dialysis patients. In our study, macro-
cytosis was a strong predictor of mortality evidenced by
a high hazard ratio. In addition, as it is included in the
routine CBC, measurement of the MCV requires no
additional laboratory tests and is cheaper compared to
conventional laboratory markers of mortality.
There are limitations to this study. With only 23 out-
comes, we were unable to do extensive multivariate ana-
lyses without risk of over-fitting. Therefore, there is the
possibility of residual confounding. However, this is pri-
marily a pilot study and the main purpose is to stimulate
hypothesis generation for future analyses. Another
Table 3 Cause of Death at Last Follow Up
All
(n = 150)
MCV < 102 fl
(n = 105)
MCV > 102 fl
(n = 45)
All Cause 23 10 13
Cardiac 7 3 4
Withdrawal 8 5 3
Sepsis 5 1 4
Cancer 2 1 1
Stroke 1 0 1
MCV<=102fl
MCV>102fl
Figure 4 Kaplan Meier survival for MCV > 102 fl.L o gr a n kp=
0.003
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levels in all patients makes it difficult to completely
exclude vitamin deficiency as a cause of macrocytosis. In
addition, only a few patients had reticulocyte levels mea-
sured at baseline (a known cause of macrocytosis). How-
ever, 93 and 100% of patients with an MCV > 102 fl were
on multivitamin and folate supplementation, and at six
months, RBC folate and serum B12 levels were normal in
over 90% of macrocytic patients (data not shown). In
addition, a reanalysis at six months revealed comparable
reticulocyte counts between macrocytic and normocytic
patients, and an absolute reticulocytosis in only a few
macrocytic patients (data not shown). Finally, as this is a
single-centre study, we acknowledge that the findings of
this study cannot necessarily be generalized to other dia-
lysis populations. A recent study in a larger cohort of dia-
lysis patients identified a lower mean MCV than our
cohort, and did not find an association between MCV
and mortality [23]. However, our study is unique as we
analyzed MCV both as a continuous and categorical vari-
able. Furthermore, our population is not unlike other dia-
lysis cohorts with respect to its identified predictors of
mortality. These predictors include age [33-36], stroke
[33,34], cancer [33,34], albumin [35] and ferritin [37,38].
Nonetheless, our population may be unique with respect
to a high prevalence of macrocytosis and validation with
another dialysis population may increase the strength of
our findings. In addition, if macrocytosis is associated
with higher comorbidity it would fluctuate based on
patient clinical status. Thus, a study using marginal struc-
tural models that adjust for time dependent confounding
would be clinically relevant.
Conclusions
Unexplained macrocytosis may be associated with mor-
tality in stable, chronic hemodialysis patients. Future
studies will need to be conducted in larger numbers of
incident hemodialysis patients to determine the signifi-
cance of this finding.
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